ZA87702B - Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like - Google Patents

Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Info

Publication number
ZA87702B
ZA87702B ZA87702A ZA87702A ZA87702B ZA 87702 B ZA87702 B ZA 87702B ZA 87702 A ZA87702 A ZA 87702A ZA 87702 A ZA87702 A ZA 87702A ZA 87702 B ZA87702 B ZA 87702B
Authority
ZA
South Africa
Prior art keywords
viral
compositions
treatment
cancerous skin
same
Prior art date
Application number
ZA87702A
Other languages
English (en)
Inventor
Maxwell M Powell
Original Assignee
Exovir Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exovir Inc filed Critical Exovir Inc
Publication of ZA87702B publication Critical patent/ZA87702B/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60D—VEHICLE CONNECTIONS
    • B60D1/00—Traction couplings; Hitches; Draw-gear; Towing devices
    • B60D1/58—Auxiliary devices
    • B60D1/66—Props
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Transportation (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA87702A 1986-02-18 1987-01-30 Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like ZA87702B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/830,662 US4822605A (en) 1986-02-18 1986-02-18 Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Publications (1)

Publication Number Publication Date
ZA87702B true ZA87702B (en) 1987-09-30

Family

ID=25257431

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA87702A ZA87702B (en) 1986-02-18 1987-01-30 Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Country Status (10)

Country Link
US (1) US4822605A (de)
EP (1) EP0233629B1 (de)
JP (1) JPS62240627A (de)
AT (1) ATE68702T1 (de)
AU (1) AU598232B2 (de)
CA (1) CA1297006C (de)
DE (1) DE3773953D1 (de)
DK (1) DK82287A (de)
IL (1) IL82351A (de)
ZA (1) ZA87702B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
US6060459A (en) * 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US6241982B1 (en) * 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US5342613A (en) * 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
DK0392300T3 (da) * 1989-04-11 1992-09-28 Boehringer Ingelheim Int Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
US5028421A (en) * 1989-05-25 1991-07-02 Embrex, Inc. Method of treating birds
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
CA2086264C (en) * 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
US5082472A (en) * 1990-11-05 1992-01-21 Mallouk Robert S Composite membrane for facilitated transport processes
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5547661A (en) * 1994-02-22 1996-08-20 Helene Curtis, Inc. Antiperspirant deodorant compositions
IL112649A (en) * 1994-02-22 1999-12-22 Curtis Helene Ind Inc Topically effective compositions for application to the skin or hair
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5547551A (en) * 1995-03-15 1996-08-20 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
USRE37701E1 (en) * 1994-11-14 2002-05-14 W. L. Gore & Associates, Inc. Integral composite membrane
US6254978B1 (en) 1994-11-14 2001-07-03 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
US5599614A (en) * 1995-03-15 1997-02-04 W. L. Gore & Associates, Inc. Integral composite membrane
USRE37307E1 (en) 1994-11-14 2001-08-07 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
SK70598A3 (en) * 1995-11-30 1999-04-13 Univ Texas Methods and compositions for the diagnosis and treatment of cancer
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
US20020041863A1 (en) * 1997-03-14 2002-04-11 Masamichi Kojiro Preventive and/or therapeutic agent for cachexia
US6130175A (en) * 1997-04-29 2000-10-10 Gore Enterprise Holdings, Inc. Integral multi-layered ion-exchange composite membranes
US6638659B1 (en) 1999-04-30 2003-10-28 University Of Connecticut Membrane electrode assemblies using ionic composite membranes
US6211243B1 (en) 1999-09-22 2001-04-03 B. Ron Johnson Methods for treating cold sores with anti-infective compositions
US8173709B2 (en) * 1999-09-22 2012-05-08 Quadex Pharmaceuticals, Llc Anti-infective methods for treating pathogen-induced disordered tissues
US6759434B2 (en) 1999-09-22 2004-07-06 B. Ron Johnson Anti-infective compositions, methods and systems for treating disordered tissue
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US6613203B1 (en) 2001-09-10 2003-09-02 Gore Enterprise Holdings Ion conducting membrane having high hardness and dimensional stability
US6668753B2 (en) 2002-02-13 2003-12-30 Embrex, Inc. Methods and apparatus for delivering fluid to egg injection devices
US6860225B2 (en) * 2002-05-06 2005-03-01 Embrex, Inc. Methods and apparatus for identifying live eggs by detecting embryo heart rate and/or motion
US7373561B2 (en) * 2002-10-29 2008-05-13 Broadcom Corporation Integrated packet bit error rate tester for 10G SERDES
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20050100601A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
ES2393761T3 (es) 2006-07-14 2012-12-27 Stiefel Research Australia Pty Ltd Espuma farmacéutica de ácido graso
EP2311481A3 (de) * 2006-10-20 2013-10-16 Biogen Idec MA Inc. Behandlung von Entmarkungserkrankungen mit löslichem Lymphotoxin-beta-rezeptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2008070317A2 (en) * 2006-11-29 2008-06-12 Redox Pharmaceutical Corporation A method for the treatment of psoriasis
WO2008103416A1 (en) * 2007-02-21 2008-08-28 Capps Charles L Synergistic enhancement of calcium propionate
CN102576891A (zh) 2009-09-03 2012-07-11 纳幕尔杜邦公司 用于直接甲醇燃料电池的具有复合材料、薄膜和薄阴极的改善的催化剂涂覆膜
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
EA201990140A1 (ru) 2016-06-28 2019-07-31 Мехмет Невзат Писак Поверхностно-активные вещества для лечения инфекций кожи, вызываемых содержащими двухцепочечную днк вирусами семейств herpesviridae или papillomaviridae

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020183A (en) * 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
US4480032A (en) * 1980-11-13 1984-10-30 Yabrov Alexander A Natural mixture of Type I and Type II interferons
DE3117934A1 (de) * 1981-05-06 1982-12-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IL71954A0 (en) * 1983-06-01 1984-09-30 Genentech Inc Gamma interferon-lymphotoxin synergism
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
EP0149551A3 (de) * 1984-01-16 1987-09-23 Genentech, Inc. Synergistische Gamma-Interferon-Interleukin-2-Zusammensetzungen und Verfahren zur Herstellung desselben
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
AU7128887A (en) * 1986-02-10 1987-08-25 Liposome Technology, Inc. Controlled-release liposome delivery system

Also Published As

Publication number Publication date
ATE68702T1 (de) 1991-11-15
AU598232B2 (en) 1990-06-21
AU6879087A (en) 1987-08-20
EP0233629A1 (de) 1987-08-26
DK82287D0 (da) 1987-02-18
JPS62240627A (ja) 1987-10-21
US4822605A (en) 1989-04-18
DE3773953D1 (de) 1991-11-28
DK82287A (da) 1987-08-19
IL82351A (en) 1990-12-23
CA1297006C (en) 1992-03-10
EP0233629B1 (de) 1991-10-23

Similar Documents

Publication Publication Date Title
ZA87702B (en) Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
AU4465285A (en) Tumor necrosis factor
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DE3278234D1 (en) Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
EP0297733A3 (de) Catecholbutane enthaltende Arzneimittel
IL75597A (en) Synergistic mixtures of interferons and tumour necrosis factor
AU638982B2 (en) Use of cytokines
IE872344L (en) Compositions suitable for human topical application¹including a growth factor and/or related materials
PT78773A (en) The effect of human tumor necrosis factor and human interferon on human cancer cells and methods
IE44431L (en) Pyrimid-2-ones
ES8704547A1 (es) Metodo para producir la proteina factor recombinante de necrosis de tumores hermanos (tnf) a partir de celulas hospedantes competentes transformadas con un vector de expresion.
NO954880L (no) Cytidin deaminase
MY123434A (en) Composition comprising il-18 and topotecan for treatment and/or prevention of cancer
IL80584A0 (en) Cardiotonic thiazolones and pharmaceutical compositions containing them
NZ219027A (en) Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
GB1052049A (de)
JPS6445314A (en) Antitumoral
SU688447A1 (ru) Стекло с анионной проводимостью по брому
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.
JPS57144217A (en) Antitumor agent
Vulimiri et al. Analysis of polar DNA adducts formed in mouse epidermis from dibenz [a, j] anthracene
CA816842A (en) Determination of combined carbon in metals
中山康子 Miroslav NOVAK und Helma OHKENDORF-GROTEWOLD: Die japanische technishwissenschaft-liche Literatur in Deutschland
GB1436816A (en) Heating apparatus